Supriya Lifescience Limited - Asset Resilience Ratio
Supriya Lifescience Limited (SUPRIYA) has an Asset Resilience Ratio of 0.58% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Supriya Lifescience Limited for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Supriya Lifescience Limited's Asset Resilience Ratio has changed over time. See SUPRIYA net asset value for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Supriya Lifescience Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see SUPRIYA market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs69.80 Million | 0.58% |
| Total Liquid Assets | Rs69.80 Million | 0.58% |
Asset Resilience Insights
- Limited Liquidity: Supriya Lifescience Limited maintains only 0.58% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Supriya Lifescience Limited Industry Peers by Asset Resilience Ratio
Compare Supriya Lifescience Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Supriya Lifescience Limited (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Supriya Lifescience Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 5.44% | Rs604.66 Million ≈ $6.54 Million |
Rs11.12 Billion ≈ $120.29 Million |
+1.64pp |
| 2024-03-31 | 3.80% | Rs350.04 Million ≈ $3.79 Million |
Rs9.21 Billion ≈ $99.63 Million |
-5.98pp |
| 2023-03-31 | 9.78% | Rs802.11 Million ≈ $8.67 Million |
Rs8.20 Billion ≈ $88.71 Million |
+1.73pp |
| 2022-03-31 | 8.05% | Rs591.55 Million ≈ $6.40 Million |
Rs7.35 Billion ≈ $79.46 Million |
-1.58pp |
| 2021-03-31 | 9.63% | Rs429.28 Million ≈ $4.64 Million |
Rs4.46 Billion ≈ $48.21 Million |
-12.12pp |
| 2020-03-31 | 21.75% | Rs731.62 Million ≈ $7.91 Million |
Rs3.36 Billion ≈ $36.38 Million |
+17.53pp |
| 2019-03-31 | 4.21% | Rs106.66 Million ≈ $1.15 Million |
Rs2.53 Billion ≈ $27.37 Million |
+1.82pp |
| 2018-03-31 | 2.39% | Rs58.74 Million ≈ $635.25K |
Rs2.45 Billion ≈ $26.54 Million |
-- |
About Supriya Lifescience Limited
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, anti"hypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary… Read more